Five separate truths
- IdentitySun Yat-sen University Cancer Center, Guangzhou, China
- CapabilityPublicly documented
- International accessNot yet verifiedUnknown, so no conclusion can be drawn.
- TanyaKanker verificationPublic reference onlyUnknown, so no conclusion can be drawn.
- Last checkedNever checkedUnknown, so no conclusion can be drawn.
- Current availability
- Unknown
- Relationship status
- Listed as a reference, with no partnership claim
- Case suitability
- Not assessed
- • A facility being listed does not mean it provides a specific capability.
- • A documented capability does not mean it is currently available.
- • Availability does not mean international patients can access it.
- • A relationship with TanyaKanker does not mean the facility is clinically best.
- • A relevant facility does not mean the patient is suitable.
University cancer center
Sun Yat-sen University Cancer Center
A large academic cancer center in Guangzhou with high patient volume.
Placeholder illustration: a photo is published only when the facility's own image is authorised.
Partnership and verification
Why this facility is on the list
The capabilities below are the ones on public record. They say what the facility documents, not how well it performs and not that it will accept a case.
- Repeatedly listed as a clinical trial site in public registries.
Nothing here states quality, price, or schedule availability.
Technologies and recorded fields
NOT VERIFIED
Departments, named specialist rosters and equipment inventory beyond the public listing are not verified.
NOT VERIFIED
Waiting time and schedule availability cannot be confirmed from a public source.
International review workflow
This is the general frame for a cross-border review. The facility confirms its own steps, and TanyaKanker does not guarantee acceptance.
Contact through the official channel
Confirm the international office and the language used for correspondence.
Send the structured case summary
Reports, imaging dates, previous treatment, and the current question.
Clinical review by the treating team
The facility decides whether the case fits its service.
Written confirmation of plan and cost
Ask for the plan, the document list, and a written estimate before any payment.
Documents usually needed
- Latest pathology or histopathology report
- Latest CT, MRI, or PET-CT, including DICOM files when available
- Summary of previous treatments and dates
- Latest laboratory results
- Biomarker or molecular test results, if available
- Discharge summary or referral letter from the treating doctor
A general frame, not the facility's own official list. Confirm the final list with the facility.
Cost state
NO FIGURE PUBLISHED
No verified written quote exists for this facility. A range can only be read after the treating team reviews the case and the facility issues a written estimate.
Registry studies with a similar facility name
These studies are recorded in the public registry with a facility name resembling this profile. A name match does not prove the study runs at this facility.
NCT06049290Phase 1 / Phase 2Combination regimen
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
China21 registry sites
Why this appears: Appears because it is recorded for Multiple Myeloma.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06049290Not verified
NCT06106802Phase 2Targeted therapy
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Lung Cancer | biomarker: EGFR, MET | Targeted therapy
South Korea1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06106802Not verified
NCT06830694Phase 2Immunotherapy
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Lung Cancer | biomarker: EGFR | Immunotherapy, Chemotherapy
South Korea1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06830694Not verified
NCT07570017Phase 1Immunotherapy
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Lymphoma | Immunotherapy, Chemotherapy
China2 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07570017Not verified
Summary
- City
- Guangzhou
- Country
- China
- Type
- University cancer center
- Last checked
- 2026-09-10
- Access status
- Not yet verified
- Partnership
- No partnership claimed
Sources
- ClinicalTrials.gov(registry)
Other facilities
Back to the facility directoryCompare and continue
Ask about international patient access
We help structure the questions to send to the facility. TanyaKanker claims no partnership and does not guarantee acceptance.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
This information is not a diagnosis or a medical recommendation. Decisions remain with your medical team.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.